On this page Agenda Applications for consideration at this meeting 1357.1 F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer 1405.1 MBS Item for Pulmonary Rehabilitation (Re-submission) 1455 Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program 1466 Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration 1498 Serum soluble transferrin receptor 1510 Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with Factor VIII inhibitors 1519 Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma 1530 Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD) 1541 Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma (OAG) Related information Committee: Evaluation Subcommittee (ESC)